Early access
Sign in
Taking people in SwitzerlandNo phase

Studying Heart Muscle Weakness Caused by Irregular Heartbeat

Collects existing data from adults suspected of having arrhythmia-induced cardiomyopathy at Basel.

Key facts

Who runs it
University Hospital, Basel, Switzerland
Where
Basel, SwitzerlandSee the site
Trial code
Registry title
Characterization of Arrhythmia-induced Cardiomyopathy
Status
Recruiting
People taking part
2,700 people, planned
Started
10 Jun 2021
Expected to end
Jan 2027
Type of study
Observational
Treatments tested
  • Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)
  • Data collection: Quality of Life (QoL) Questionnaire (prospective part)
  • Data collection (retrospective study)
  • Data collection (prospective study database)
Record updated
4 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have, or are suspected to have, a heart muscle problem caused by an irregular heartbeat (arrhythmia-induced cardiomyopathy), treated at the University Hospital Basel.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Prospective part: diagnosis or suspicion of arrhythmia-induced cardiomyopathy. Retrospective part: reduced left-ventricular ejection fraction (LVEF ≤50%) or a 15% drop in ejection fraction between two echocardiographies, together with an arrhythmia likely to cause it, within one year before or after the diagnosis, from 2010-2021.

Main reasons for not taking part

  • Under 18 years old
  • Refuses the general consent of the University Hospital Basel
  • Life expectancy under 1 year (palliative care, terminal cancer)
  • Acute event that clearly caused the reduced ejection fraction, such as a massive heart attack, cardiogenic shock, septic shock, hypovolemic shock or cardiac arrest
  • Prospective part, temporary: acute illness such as heart attack, major trauma, sepsis, recent cardiac surgery or shock

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Diagnostic or suspicion of AiCM as presence of specified keyword in patient's file or as screened by colleagues of the internal medicine or cardiology clinics
  • Signed study consent
  • Patients with a reduced left-ventricular ejection fraction (LVEF ≤50%) or a reduction of 15% in the ejection fraction (EF) between two echocardiographies and a concomitant diagnosis of any arrhythmia likely to lead to AiCM within one year before or after diagnosis of the reduced LVEF from 2010-2021

Who cannot take part

  • Temporary exclusion criteria: Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (>100 bpm, <90 systolic BP, evidence of organ dysfunction)
  • Life expectancy <1 year (palliative, terminal cancer); Retrospective part
  • Patients with life expectancy <1 year (palliative, terminal cancer)
  • Acute event clearly leading to an acutely reduced LVEF (massive type I myocardial infarction, cardiogenic shock from a coronary or myocardial etiology, septic shock leading to toxic myopathy, hypovolemic shock with reduced EF, cardiac arrest and/or need for resuscitation)
  • Age <18 years old
  • Age < 18 years old
  • Patient's active refusal of the general consent of the University Hospital Basel
  • Patient's active refusal of the general consent of the University Hospital Basel

Other criteria

  • Prospective part

Where in Switzerland

  • University Hospital Basel, Department of CardiologyBasel, SwitzerlandContact: Patrick Badertscher, MDTaking people

About the trial

What the trial wants to find out

The goal of the this observational study is to gather clinically available data on patients presenting with a suspicion for arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel.

The group in the trial

  • Patients with arrhythmia-induced cardiomyopathy (retrospective/prospective)

    retrospective cohort and case-control study followed by a prospective observational cohort study.

    Treatment: Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part), Data collection: Quality of Life (QoL) Questionnaire (prospective part), Data collection (retrospective study), and Data collection (prospective study database)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Arrhythmia-induced Cardiomyopathy - a Prospective Observational Cohort Study
Plain-language title
Studying Heart Muscle Weakness Caused by Irregular HeartbeatGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 March 2025